Ovarian Hormone Disorder PMOS May Raise Alzheimer’s and Dementia Risk, Review Finds

A hormonal condition that affects as many as one in seven women worldwide may leave fingerprints on the aging brain. A new review of existing evidence, published in the Journal of the Endocrine Society, suggests that polyendocrine metabolic ovarian syndrome, or PMOS, the condition long known as polycystic ovary syndrome, may be associated with an elevated risk of Alzheimer’s disease and related dementias. The finding adds a neurological dimension to a disorder already tied to diabetes, heart disease, stroke, depression, anxiety, infertility and endometrial cancer, and it raises urgent questions about how a reproductive-metabolic condition diagnosed in early adulthood could shape cognitive health decades later.

The renaming of polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome reflects a growing recognition among endocrinologists that the condition extends far beyond the ovaries. What was once framed primarily as a gynecological problem characterized by irregular ovulation and cystic-appearing ovaries is now understood as a systemic endocrine disorder involving insulin resistance, altered androgen production, and disordered energy metabolism. This reframing matters for the dementia question because it places PMOS squarely within a family of metabolic conditions already known to influence brain aging. Type 2 diabetes, obesity, and metabolic syndrome have each been associated in large population studies with increased dementia risk, and the mechanisms implicated in those associations overlap substantially with the pathways the review’s authors highlight.

Insulin resistance deserves particular attention when considering how PMOS might connect to Alzheimer’s disease. The brain is an insulin-responsive organ, and insulin signaling in the central nervous system participates in neuronal survival, synaptic plasticity, and the clearance of amyloid-beta, the protein fragment that accumulates in the plaques characteristic of Alzheimer’s pathology. Some researchers have even described Alzheimer’s disease as carrying features of an insulin-resistant state of the brain, sometimes informally labeled type 3 diabetes, although that phrase remains contested and should not be read as a claim that Alzheimer’s is simply diabetes of the brain. What is better established is that peripheral insulin resistance, of the kind frequently observed in PMOS, correlates with reduced cerebral glucose metabolism and altered amyloid handling in imaging studies of middle-aged and older adults.

Obesity adds a second plausible conduit between PMOS and dementia. Adipose tissue is not merely a passive energy depot; it is an active endocrine organ that secretes inflammatory cytokines, adipokines, and other signaling molecules. Chronic low-grade inflammation driven by excess visceral fat has been linked to vascular damage, blood-brain barrier dysfunction, and accelerated cognitive decline in multiple cohorts. Midlife obesity in particular has emerged as a consistent risk factor for later-life dementia in observational research, while the relationship with obesity in late life is more complicated and sometimes reversed, a pattern that may reflect weight loss preceding clinical dementia. Because women with PMOS commonly carry excess weight from early adulthood, their cumulative lifetime exposure to obesity-related inflammatory and vascular stress may be substantially longer than average.

The vascular dimension is worth emphasizing. PMOS is associated with elevated blood pressure, adverse lipid profiles, and impaired endothelial function, all of which contribute to cerebrovascular disease. Vascular contributions to cognitive impairment and dementia are increasingly recognized as major and potentially modifiable factors, and they frequently coexist with Alzheimer-type pathology. A woman whose PMOS accelerates hypertension or dyslipidemia in her thirties and forties could plausibly enter her sixties and seventies with a brain already bearing the cumulative marks of compromised blood flow, small vessel damage, and microbleeds. This pathway would not require PMOS to act independently on neural tissue at all; it would simply extend the syndrome’s known cardiometabolic consequences into the cerebral circulation.

Androgens represent a third candidate mechanism, and one that is less well understood. PMOS is characterized by elevated ovarian or adrenal androgen production, and androgen signaling interacts with estrogen pathways in ways that vary across the life course. Estrogen has long been studied for its neuroprotective properties, and the sharp decline of estrogen at menopause has been proposed as one reason women face higher Alzheimer’s risk than men overall. How chronically elevated androgens, altered estrogen-to-androgen ratios, and the hormonal shifts of midlife combine in women with PMOS remains largely uncharted. Some animal studies suggest androgen excess can influence hippocampal structure and function, but translating those findings to human cognitive aging requires far more evidence.

The cognitive findings described in the review, mild but reproducible impairments in executive function and memory among PMOS patients, align with patterns seen in other metabolic and psychiatric conditions. Executive function, which governs planning, working memory, and cognitive flexibility, is particularly sensitive to vascular health and to depression, both of which are more common in PMOS. It is therefore possible that some of the cognitive differences observed in younger and middle-aged PMOS populations reflect mood symptoms, sleep disturbance, or metabolic burden rather than incipient neurodegenerative disease. Depression and anxiety, which the review notes are common in PMOS, are themselves established risk factors for later dementia, adding yet another thread to an already tangled web of associations.

Disentangling these threads is the central methodological challenge facing this field. Most available evidence comes from cross-sectional studies or administrative databases, which can identify associations but cannot establish that PMOS causes dementia or that treating PMOS would lower dementia risk. Confounding is a serious concern: women diagnosed with PMOS differ from unaffected women in weight, socioeconomic factors, healthcare utilization, and comorbid conditions, any of which could account for apparent differences in cognitive outcomes. Reverse causation is unlikely in this direction, since PMOS begins in reproductive years long before dementia onset, but selection bias in who gets diagnosed and who gets studied remains a real limitation. The review’s authors acknowledge these gaps explicitly, which is appropriate given the state of the evidence.

Large longitudinal cohorts that follow women with well-characterized PMOS from midlife into older age would be the most direct way to test whether the syndrome independently predicts dementia incidence. Such studies would need to measure metabolic markers serially, distinguish between the different phenotypic presentations of PMOS, and account for treatments that may themselves modify risk. Metformin, the most commonly prescribed medication for insulin resistance in PMOS, has been examined in some dementia-prevention research with mixed results, and oral contraceptives, another mainstay of PMOS management, alter hormonal milieu in ways whose long-term neurological consequences are incompletely mapped. Lifestyle interventions that improve insulin sensitivity and reduce weight are already recommended for PMOS and carry well-documented benefits for vascular and metabolic health, so any overlap with dementia-prevention strategies would be clinically convenient.

The demographic stakes are considerable. Women constitute roughly two-thirds of people living with Alzheimer’s disease, a disparity only partly explained by longer female life expectancy. If a common condition affecting ten to fifteen percent of women modulates that risk, even modestly, the population-level impact could be substantial. At the same time, there is a risk of overinterpreting preliminary associations in ways that alarm patients. The current evidence does not establish that most women with PMOS will develop dementia, nor does it identify a specific age at which risk diverges. What it does establish is a credible biological rationale and enough suggestive clinical signal to justify rigorous investigation.

For clinicians caring for women with PMOS today, the practical message is continuity rather than novelty. The same measures already recommended to reduce the syndrome’s cardiometabolic burden, including weight management, physical activity, glycemic control, and attention to blood pressure and lipids, are the measures most consistently associated with preserved cognitive health in aging populations. Framing PMOS as a lifelong condition with consequences extending into the brain’s later years may help motivate sustained engagement with those interventions during the decades when they matter most. It also underscores the importance of integrating reproductive, metabolic, and neurological perspectives rather than treating each specialty’s concerns in isolation, a lesson that extends well beyond this single syndrome to the broader study of how women’s health across the life course shapes the aging brain.

Subject of Research: Potential association between polyendocrine metabolic ovarian syndrome and Alzheimer's disease and dementia

Article Title: PMOS/PCOS may be linked to Alzheimer's disease and dementia

Article References: PMOS/PCOS may be linked to Alzheimer's disease and dementia. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: PMOS, PCOS, Alzheimer's disease, dementia, insulin resistance, obesity, women's health, endocrinology, metabolic syndrome, brain health, executive function, Journal of the Endocrine Society